CARLSBAD, Calif., Nov. 29, 2017 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (NASDAQ:NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that on November 22, 2017, the U.S. Patent and Trademark Office issued a Notice of Allowance for NAI’s patent application entitled “Compositions and Methods for the Sustained Release of Beta-Alanine.” The newly allowed application becomes part of NAI’s global patent estate covering its SR CarnoSyn® beta-alanine product.
Mark A. LeDoux, NAI’s CEO and Chairman of the Board, said, “This new patent is another integral component of NAI’s SR CarnoSyn® beta-alanine patent portfolio. These claims are an important part of our global strategy for providing performance increases well beyond those achievable through normal diets.” NAI’s allowed application contains claims directed to human and animal dietary supplements containing sustained release beta-alanine in formulations that permit the release of beta-alanine over time. The unique sustained release provides a steady, manageable rate of release following consumption, which helps the body’s uptake of beta-alanine to form carnosine via a steady presence over time of beta-alanine in the blood system.
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI’s clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at http://www.nai-online.com.
This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our beta-alanine patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
CONTACT – Kenneth Wolf, President, Natural Alternatives International, Inc., at 760-736-7700 or [email protected]nline.com.
View original content:http://www.prnewswire.com/news-releases/natural-alternatives-international-inc-announces-allowance-of-new-us-sustained-release-beta-alanine-patent-application-300564045.html